Methodology
How we grade evidence, how to read drug cards, how supplements differ from medicines.
This section explains how Evigrade builds its evidence assessments. The drug card traffic-light system relies on a research hierarchy: systematic reviews and meta-analyses (green tier), high-quality RCTs (green), RCTs with limitations (yellow), observational cohorts (yellow), and case series and in vitro studies (red). Regulatory sources are distinguished: international society guidelines (ESC, ESH, EASL, AASLD, ESMO) and Russian Ministry of Health clinical recommendations. Sources are cited by DOI or PubMed link for every statement. This section is for readers who want to understand exactly what the traffic light rests on and why the same drug can hold different ratings across different indications.
- Featured#lactancia#lactapp#mission
Continuing the mission: how Evigrade closes the gap in lactation tools
LactApp entered insolvency proceedings in November 2025 after 8 years of work and 50,000 active users in Spain. It is a loss for the million-plus mothers who relied on it. Here is what Evigrade is doing to close the remaining gap: cross-category coverage (drugs + cosmetics + supplements), evidence base on every card, and a sustainable business model that does not depend on grants.
- Featured#supplements#evidence-based#drug-regulation
Supplements vs medicines: why even working molecules belong in a drug form
The difference between a supplement and a medicine lies in the regulatory framework, not the molecule. Clinical trials, GMP, batch control – all standard for medicines, largely absent for supplements. With specific numbers from JAMA, ConsumerLab, Cochrane, and independent melatonin and omega-3 testing.